PRGS · Investment summary · as of 30 July 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The business does not meet the quality standard for its economic type.
At $40.01, the gap between what the price requires and what the business has demonstrated is +3.3 percentage points.
The value rests on an exit multiple of 15.8x and a terminal operating margin of 18%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Cause: the revolver stops being available on the terms the model assumes.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Not determined — the operating driver is not stated in one place |
| What do we forecast? | A terminal operating margin of 18%; an exit multiple of 15.8x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +3.3 percentage points. |
| What is it worth? | Twelve-month target $44.43, +11% from the struck price. Scenario-weighted expected return net of costs +11.1%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Not determined — no falsifiable operating conditions are on file for this name, so the thesis cannot be reduced to a small number of testable claims
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 5 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Cause: the revolver stops being available on the terms the model assumes. PRGS carries $850m drawn on a $1.5bn facility at 5.92%, net debt/EBITDA around 3.5x, and organic revenue that is shrinking. If the next deal cannot be funded — because leverage covenants bind, or because the facility reprices — the reported growth rate converges on the organic rate, which is −2.2% on revenue and +2% on ARR. At a −2% revenue path and a 15.7% GAAP margin, EBIT falls to roughly $155m by FY2029 and the equity, which is 42% geared, absorbs the whole of any multiple compression. At the ROIC-warranted 7.2x EV/E
Not determined — no falsifiable invalidation conditions are on file, so this position cannot be risk-monitored
On approach to the $44.43 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | Cause: the revolver stops being available on the terms the model assumes. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +3.3 percentage points more growth than the price requires. The most important unresolved uncertainty is whether a position could be built and exited at the intended size. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $34.25, which forces an immediate review.